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LETTER TO THE EDITOR Open Access
Cautionary optimism: caffeine and
Parkinson’s disease risk
Leonard L. Sokol1†, Michael J. Young2†, Alberto J. Espay1 and Ronald B. Postuma3*
Abstract
Most Parkinson’s disease (PD) patients present without known family history and without a diagnosed prodromal
phase, underscoring the difficulty of employing primary (neuroprevention) and secondary (neuroprotection)
preventions. In cases of monogenic forms, however, potential gene-carrying family members of a proband could
engage in neuroprevention, such as exercise or diet modifications, to attenuate the risk of, or delay, disease
development. However, a historical lack of recognized disease-modifying interventions has limited clinicians’
ability to recommend reliable preventive measures in caring for at-risk populations. We briefly analyze the first
retrospective study to examine caffeine consumption and PD risk in a LRRK2 R1628P cohort.
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Letter to the Editor
Caffeine is strongly associated with reduced risk of
Parkinson’s disease (PD). Meta-analyses [1, 2] suggest
that non-users have a higher PD risk in a notably dose-
dependent fashion [2]. The underlying mechanism for this
apparent effect is unclear. Potential explanations include a
true neuroprotective benefit (supported by some animal
models finding benefits of A2A antagonism [3]), a symp-
tomatic effect which delays diagnosis (supported by pre-
liminary evidence of motor benefit of caffeine in small
randomized controlled trials [4]), reverse confounding
(prodromal parkinsonism reduces caffeine intake via
changes in tolerability or reward mechanisms such as has
been suggested for smoking [5]), or confounding by an-
other unmeasured factor (e.g., the putative Parkinson
personality [6]).
Most recently, a new case–control study [7] examined
caffeine consumption and PD risk in a gene-carrier
(LRRK2 R1628P) cohort of Chinese patients. LRRK2
R1628P is a low-penetrance variant that has been associ-
ated with increased PD risk in mainly Asian populations,
with an odds ratio (OR) ranging from 1.20 to 2.83 [8].
The study included 378 PD subjects and 434 healthy
controls (PD median age: 66 years; controls: 60). For OR
calculations, the authors defined the reference group
(PD cases: 257; controls: 369) as those with the LRRK2
wildtype allele who had a reported history of caffeine
consumption. Gene-carrier caffeine-abstainers had a
15.4 (95 % CI = 1.94,122.3, n = 11) OR of PD; by contrast,
gene-carrier caffeine-consumers had a lower increased OR
of 3.07 (2.02-4.66, n = 33). On the basis of these data, the
study authors suggest that caffeine intake may be associ-
ated with reduced risk of PD development especially in
those who are gene-carriers.
Some caveats should be considered when interpreting
these results. First, the sample size was insufficient to
provide an estimate of a true effect, as within the R1628P
sample, there were too few PD cases (n = 28; 18 caffeine-
consumers and 10 caffeine-abstainers) and controls
(n = 16; 15 caffeine-consumers and 1 caffeine-abstainer),
yielding an imprecise OR (1.94 to 122.3) that clearly over-
lapped with the OR for gene-carrier caffeine-consumers.
Second, recall bias or other sources of measurement error
may have influenced the interpretation of the PD environ-
mental risk factor questionnaire. Third, it is unclear what
number of multiple hypotheses were tested in this cohort;
if dozens of potential gene-environment interactions were
queried, the chances of a spurious result are high. It
should be cautioned that many gene-environment findings
based upon single cohort studies are not reproduced. Fi-
nally, the physiologic mechanism(s) governing the putative
impact of caffeine in the PD neurodegenerative cascade
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remains unclear. Recognizing the excitement that the
prima-facie favorable findings of this study may generate
among patients and clinicians, these key caveats should be
considered in the course of crafting an evidence-based
and patient-centered approach to neuropreventive coun-
seling and care.
While this study was neither definitive nor generalizable,
it suggests the possibility that disease subtypes may have
different environmental risk profiles. Of note, LRRK2 in
PD is characterized by inconsistent deposition of synu-
clein, and a corresponding lower prevalence of non-motor
manifestation such as REM sleep behavior disorder (RBD)
and dementia [9]. A recent case control study of patients
with idiopathic RBD found that caffeine use did not pro-
tect against future development of PD; this is the only
prospective study that has ever failed to find a caffeine
effect [10]. If there is an RBD subtype of PD that does not
respond to caffeine, then might non-RBD subtypes re-
spond even more?
If such a study is replicated in a larger series—which is
critical for ascertainment of such gene-environmental
interactions—it may have implications for other well-
known LRRK2 variants, such as G2019S, which has a
calculated disease penetrance of 26 % by age 80 [11].
Might caffeine have a similar interaction? If so, might
such patients benefit from using caffeine? Without bet-
ter evidence, there remain dichotomous perspectives
[12, 13] on how to counsel carriers and their families.
Research that examines how environmental behaviors
might attenuate PD susceptibility is warranted [11], as is
further investigation on how to counsel such a vulnerable
cohort [14].
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